Role of interferon‐alpha administration after 2‐deoxycoformycin in the treatment of hairy cell leukemia patients

Marotta, Giuseppe; Frassoldati, Antonio; Zinzani, Pier Luigi; Annino, Luciana; Brugiatelli, Maura; Ambrosetti, Achille; Lenoci, Mariapia; Fédérico, Massimo; Foà, Robin; Lauria, Francesco

doi:10.1111/j.1600-0609.2006.00670.x

Cited by 7 publications

(3 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results are similar to those from three previous studies using long‐term IFN maintenance therapy in 41, 34 and 35 patients, respectively 9–11 . In contrast to these studies, a multi‐centre Italian study evaluating IFN as adjuvant therapy (3mU s.c. thrice weekly) for 6 months following 2‐deoxycoformycin therapy did not show any difference in the proportion or duration of remissions 12 …”

Section: Discussionmentioning

confidence: 75%

Sustained long‐term remissions with weekly interferon maintenance therapy in hairy cell leukemia

Ramakrishna

Manoharan

2010

Asia-Pac J Clncl Oncology

View full text Add to dashboard Cite

Our results are similar to those from three previous studies using long-term IFN maintenance therapy, bringing the total number of patients in sustained remission to 118. We hope these reports will lead to a multi-centre, phase III study of IFN maintenance therapy (including pegylated IFN, given less frequently) in HCL patients achieving optimal response to initial therapy, be it IFN or a purine analogue.

show abstract

Section: Discussionmentioning

confidence: 75%

Sustained long‐term remissions with weekly interferon maintenance therapy in hairy cell leukemia

Ramakrishna

Manoharan

2010

Asia-Pac J Clncl Oncology

View full text Add to dashboard Cite

show abstract

“…Marotta et al randomized 145 patients that had a response to DCF (CR or PR) to receive IFN-a or not. The results showed that there were no differences between the two arms regarding improvement of response or progression free of disease [42]. …”

Section: Interferon-alphamentioning

confidence: 69%

Orphan drugs for the treatment of hairy cell leukemia

Matutes

2012

Expert Opinion on Orphan Drugs

View full text Add to dashboard Cite

“…Clinical indications IFNa Small cell lung carcinoma [4] Actinic keratoses [5] Behcet's disease [6] Mycosis fungoides [7] Discoid lupus erythematosus [8] Haemangiomas [9] Hairy cell leukaemia [10] Multiple myeloma [11] Hodgkin's lymphoma [12] Non-Hodgkin's lymphoma [13] IFNb…”

Section: Generic Namementioning

confidence: 99%

Type I interferon therapy and its role in autoimmunity

2010

View full text Add to dashboard Cite

Interferons (IFNs) display a pleiotropic effect on different cell types of both the innate and the adaptive immunities being able to affect the immune responses. The ability of IFNs, and in particular of type I IFN, to activate dendritic cells and to modulate the expression of major histocompatibility classes I and II molecules supports their potential role also in the development and maintenance of tolerance. When tolerance breakdown has occurred, immunocomplexes generated by the reaction of nuclear antigens and specific autoantibodies can further induce type I IFN production. Accordingly, high acid-labile type I IFN plasma levels, overexpression of IFNalpha-induced transcripts and the association with genes closely related to type I IFN response represent the rationale for the so-called IFN signature in systemic lupus erythematosus, a prototypical autoimmune disease. The role of IFNs in autoimmunity is further supported by their direct and deleterious impact on target tissues. The therapeutic use of IFNs is based on their antiviral and antiproliferative effect. Type I IFN administration, in particular, is associated with the appearance of autoimmunity, although less frequently than expected. Such an event takes place mostly in patients with previous autoimmune manifestations and can be characterized by the appearance of autoantibodies only or of a clinically overt disease. IFN therapy cessation is usually, but not always, required for controlling the autoimmune disorders.

show abstract

Role of interferon‐alpha administration after 2‐deoxycoformycin in the treatment of hairy cell leukemia patients

Abstract: From our data there does not appear to be any significant role for IFN-alpha in improving the proportion and the duration of CR in HCL patients previously treated with DCF.

Cited by 7 publications

References 17 publications

Sustained long‐term remissions with weekly interferon maintenance therapy in hairy cell leukemia

Sustained long‐term remissions with weekly interferon maintenance therapy in hairy cell leukemia

Orphan drugs for the treatment of hairy cell leukemia

Type I interferon therapy and its role in autoimmunity

Contact Info

Product

Resources

About